Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter

Results in Immunology

Volumn 2, Issue , 2012, Pages 174-183

  Pisapia, Laura ^a   Pozzo, Giovanna Del ^a   Barba, Pasquale ^a   Citro, Alessandra ^b,c   Harris, Paul E ^b   Maffei, Antonella ^a,b  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b Department of Medicine   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CIITA promoter IV; IFN ; MHCII; Non professional antigen presenting cells

Indexed keywords

ALPHA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CIITA TYPE IV; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DOWN REGULATION;

EID: 84867310486     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2012.09.001     Document Type: Article

References (77)

1. Janeway C.A., Bottomly K., Babich J., Conrad P., Conzen S., Jones B., Kaye J., Katz M., McVay L., Murphy D.B., Tite J. Quantitative variation in la antigen expression plays a central role in immune regulation. Immunology Today 1984, 5:99-105.
2. Christinck E.R., Luscher M.A., Barber B.H., Williams D.B. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991, 352:67-70.
3. 3/IL-4 ratios in immune responsesin vivo. Cellular Immunology 1998, 183:70-79.
4. Steimle V., Siegrist C.A., Mottet A., Lisowska-Grospierre B., Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994, 265:106-109.
5. Viret C., Janeway Jr C.A. MHC and T cell development. Reviews in Immunogenetics 1999, 1:91-104.
6. Harris P.E., Malanga D., Liu Z., Hardy M.A., Souza F., Del Pozzo G., Winchester R.J., Maffei A. Effect of interferon alpha on MHC class II gene expression in ex vivo human islet tissue. Biochimica et Biophysica Acta 2006, 1762:627-635.
7. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nature Medicine 2000, 6:1399-1402.
8. Muczynski K.A., Ekle D.M., Coder D.M., Anderson S.K. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. Journal of the American Society of Nephrology 2003, 14:1336-1348.
9. Deffrennes V., Vedrenne J., Stolzenberg M.-C., Piskurich J., Barbieri G., Ting J.P., Charron D., Alcaide-Loridan C. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B Cell-specific promoter. Journal of Immunology 2001, 167:98-106.
10. Goodwin B.L., Xi H., Tejiram R., Eason D.D., Ghosh N., Wright K.L., Nagarajan U., Boss J.M., Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth and Differentiation 2001, 12:327-335.
11. Guardiola J., Maffei A. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases. Critical Reviews in Immunology 1993, 13:247-268.
12. Game D.S., Lechler R.I. Pathways of allorecognition: implications for transplantation tolerance. Transplant Immunology 2002, 10:101-108.
13. Accolla R.S., Jotterand-Bellomo M., Scarpellino L., Maffei A., Carra G., Guardiola J. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. Journal of Experimental Medicine 1986, 164:369-374.
14. Ting J.P., Trowsdale J. Genetic control of MHC class II expression. Cell 2002, 109(Suppl.):S21-S33.
15. Muhlethaler-Mottet A., Otten L.A., Steimle V., Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO Journal 1997, 16:2851-2860.
16. Masternak K., Reith W. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation. EMBO Journal 2002, 21:1379-1388.
17. Piskurich J.F., Gilbert C.A., Ashley B.D., Zhao M., Chen H., Wu J., Bolick S.C., Wright K.L. Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma. Molecular Immunology 2006, 43:519-528.
18. Honey K., Rudensky A. The pIV-otal class II transactivator promoter regulates major histocompatibility complex class II expression in the thymus. Journal of Experimental Medicine 2001, 194:F15-F18.
19. Chen H., Gilbert C.A., Hudson J.A., Bolick S.C., Wright K.L., Piskurich J.F. Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter. Molecular Immunology 2007, 44:1461-1470.
20. Lee Y.J., Han Y., Lu H.T., Nguyen V., Qin H., Howe P.H., Hocevar B.A., Boss J.M., Ransohoff R.M., Benveniste E.N. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. Journal of Immunology 1997, 158:2065-2075.
21. Morris A.C., Spangler W.E., Boss J.M. Methylation of class II trans-activator promoter IV:a novel mechanism of MHC class II gene control. Journal of Immunology 2000, 164:4143-4149.
22. Nandan D., Reiner N.E. TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-gamma action. Journal of Immunology 1997, 158:1095-1101.
23. Piskurich J.F., Wang Y., Linhoff M.W., White L.C., Ting J.P. Identification of distinct regions of 5' flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. Journal of Immunology 1998, 160:233-240.
24. Radosevich M., Jager M., Ono S.J. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator. Experimental and Molecular Pathology 2007, 82:68-76.
25. Satoh A., Toyota M., Ikeda H., Morimoto Y., Akino K., Mita H., Suzuki H., Sasaki Y., Kanaseki T., Takamura Y., Soejima H., Urano T., Yanagihara K., Endo T., Hinoda Y., Fujita M., Hosokawa M., Sato N., Tokino T., Imai K. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-[gamma]-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 2004, 23:8876-8886.
26. van den Elsen P.J., van der Stoep N., Yazawa T. Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not. American Journal of Pathology 2003, 163:373-376.
27. Waldburger J.-M., Suter T., Fontana A., Acha-Orbea H., Reith W. Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. Journal of Experimental Medicine 2001, 194:393-406.
28. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annual Review of Immunology 2005, 23:307-335.
29. Belardelli F., Ferrantini M., Proietti E., Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokineand Growth Factor Reviews 2002, 13:119-134.
30. Lu H.T., Riley J.L., Babcock G.T., Huston M., Stark G.R., Boss J.M., Ransohoff R.M. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. Journal of Experimental Medicine 1995, 182:1517-1525.
31. Huang S., Bucana C.D., Van Arsdall M., Fidler I.J. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 2002, 21:2504-2512.
32. Lesinski G.B., Anghelina M., Zimmerer J., Bakalakos T., Badgwell B., Parihar R., Hu Y., Becknell B., Abood G., Chaudhury A.R., Magro C., Durbin J., Carson 3rd W.E. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. Journal of Clinical Investigation 2003, 112:170-180.
33. Lesinski G.B., Trefry J., Brasdovich M., Kondadasula S.V., Sackey K., Zimmerer J.M., Chaudhury A.R., Yu L., Zhang X., Crespin T.R., Walker M.J., Carson III W.E. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-{alpha} compared with immune effector cells. Clinical Cancer Research 2007, 13:5010-5019.
34. Xi H., Blanck G. The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1. Molecular Immunology 2003, 39:677-684.
35. Zhao W., Cha E.N., Lee C., Park C.Y., Schindler C. Stat2-dependent regulation of MHC class II expression. Journal of Immunology 2007, 179:463-471.
36. Doneda L., Ginelli E., Agresti A., Larizza L. In situ hybridization analysis of interstitial C-heterochromatin in marker chromosomes of two human melanomas. Cancer Research 1989, 49:433-438.
37. Tsuchida T., Ravindranath M.H., Saxton R.E., Irie R.F. Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Research 1987, 47:1278-1281.
38. Carey T.E., Takahashi T., Resnick L.A., Oettgen H.F., Old L.J. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proceedings of the National Academy of Sciences of the United States of America 1976, 73:3278-3282.
39. Ponten J., Macintyre E.H. Long term culture of normal and neoplastic human glia. Acta Pathologica Microbiologica Scandinavica 1968, 74:465-486.
40. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
41. Winchester R.J., Wang C.-Y., Gibofsky A., Kunkel H.G., Lloyd K.O., Old L.J. Expression of Ia-like antigens on cultured human malignant melanoma cell lines. Proceedings of the National Academy of Sciences of the United States of America 1978, 75:6235-6239.
42. Takamura Y., Ikeda H., Kanaseki T., Toyota M., Tokino T., Imai K., Houkin K., Sato N. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). Glia 2004, 45:392-405.
43. Brady M.S., Lee F., Petrie H., Eckels D.D., Lee J.S. CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro. Cancer Immunology, Immunotherapy 2000, 48:621-626.
44. Soos J.M., Krieger J.I., Stuve O., King C.L., Patarroyo J.C., Aldape K., Wosik K., Slavin A.J., Nelson P.A., Antel J.P., Zamvil S.S. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation. Glia 2001, 36:391-405.
45. Basham T.Y., Bourgeade M.F., Creasey A.A., Merigan T.C. Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proceedings of the National Academy of Sciences of the United States of America 1982, 79:3265-3269.
46. Piskurich J.F., Linhoff M.W., Wang Y., Ting J.P. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Molecular and Cellular Biology 1999, 19:431-440.
47. Darnell Jr J.E. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. Journal of Interferon, Cytokine and Mediator Research 1998, 18:549-554.
48. Alexander W.S. Suppressors of cytokine signalling (SOCS) in the immune system. Nature Reviews Immunology 2002, 2:410-416.
49. Fenner J.E., Starr R., Cornish A.L., Zhang J.G., Metcalf D., Schreiber R.D., Sheehan K., Hilton D.J., Alexander W.S., Hertzog P.J. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nature Immunology 2006, 7:33-39.
50. O'Keefe G.M., Nguyen V.T., Ping Tang L., Benveniste E.N. IFN-{{gamma}} regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein. Journal of Immunology 2001, 166:2260-2269.
51. Eason D.D., Blanck G. High level class II trans-activator induction does not occur with transient activation of the IFN-{{gamma}} signaling pathway. Journal of Immunology 2001, 166:1041-1048.
52. Kim H., Suh J.M., Hwang E.S., Kim D.W., Chung H.K., Song J.H., Hwang J.H., Park K.C., Ro H.K., Jo E.-K., Chang J.-S., Lee T.-H., Lee M.-S., Kohn L.D., Shong M. Thyrotropin-mediated repression of class II trans-activator expression in thyroid cells: involvement of STAT3 and suppressor of cytokine signaling. Journal of Immunology 2003, 171:616-627.
53. Lehtonen A., Matikainen S., Julkunen I. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. Journal of Immunology 1997, 159:794-803.
54. Agarwala S. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way. American Journal of Clinical Dermatology 2003, 4:333-346.
55. Chang C.H., Fontes J.D., Peterlin M., Flavell R.A. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. Journal of Experimental Medicine 1994, 180:1367-1374.
56. Morris A.C., Beresford G.W., Mooney M.R., Boss J.M. Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Molecular and Cellular Biology 2002, 22:4781-4791.
57. Pai R.K., Askew D., Boom W.H., Harding C.V. Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. Journal of Immunology 2002, 169:1326-1333.
58. Wright K.L., Ting J.P. Epigenetic regulation of MHC-II and CIITA genes. Trends inImmunology 2006, 27:405-412.
59. Park C., Li S., Cha E., Schindler C. Immune response in Stat2 knockout mice. Immunity 2000, 13:795-804.
60. Leung S., Qureshi S., Kerr I., Darnell Jr J., Stark G. Role of STAT2 in the alpha interferon signaling pathway. Molecular and Cellular Biology 1995, 15:1312-1317.
61. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Reviews Immunology 2005, 5:375-386.
62. Decker T., Lew D.J., Mirkovitch J., Darnell Jr J.E. Cytoplasmic activation of GAF, an IFN-gamma-regulated DNA-binding factor. EMBO Journal 1991, 10:927-932.
63. Shuai K., Schindler C., Prezioso V.R., Darnell Jr J.E. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992, 258:1808-1812.
64. Adolf G.R., Pieler C., Maurer-Fogy I. Constitutive production of interferon-alpha 2 by a human B-lymphoblastoid cell line. Journal of Interferon Research 1992, 12:275-280.
65. van der Stoep N, Quinten E., Alblas G., Plancke A., van Eggermond M.C.J.A., Holling T.M., van den Elsen P.J. Constitutive and IFN[gamma]-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region. Molecular Immunology 2007, 44:2036-2046.
66. Wesoly J., Szweykowska-Kulinska Z., Bluyssen H.A. STAT activation and differential complex formation dictate selectivity of interferon responses. Acta Biochimica Polonica 2007, 54:27-38.
67. Giroux M., Schmidt M., Descoteaux A. IFN-{gamma}-induced MHC class II expression: transactivation of class II transactivator promoter IV by IFN regulatory factor-1 is regulated by protein kinase C-{alpha}. Journal ofImmunology 2003, 171:4187-4194.
68. Zimmerer J.M., Lesinski G.B., Kondadasula S.V., Karpa V.I., Lehman A., RayChaudhury A., Becknell B., Carson III W.E. IFN-{alpha}-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. Journal ofImmunology 2007, 178:4832-4845.
69. Kile B.T., Schulman B.A., Alexander W.S., Nicola N.A., Martin H.M.E., Hilton D.J. The SOCS box: a tale of destruction and degradation. Trends in Biochemical Sciences 2002, 27:235-241.
70. Song M.M., Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. Journal of Biological Chemistry 1998, 273:35056-35062.
71. 3 signal transduction in vitro and in vivo. Journal of Biological Chemistry 2001, 276:22086-22089.
72. Al-Lamki R.S., Bradley J.R., Pober J.S. Endothelial cells in allograft rejection. Transplantation 2008, 86:1340-1348.
73. Nickoloff B.J., Turka L.A. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunology Today 1994, 15:464-469.
74. Taflin C, Charron D, Glotz D, Mooney N. Immunological function of the endothelial cell within the setting of organ transplantation. Immunology Letters 2011: 139, 1-6.
75. Accolla R.S., De Lerma Barbaro A., Mazza S., Casoli C., De Maria A., Tosi G. The MHC class II transactivator: prey and hunter in infectious diseases. Trends inImmunology 2001, 22:560-563.
76. Hegde N.R., Chevalier M.S., Johnson D.C. Viral inhibition of MHC class II antigen presentation. Trends in Immunology 2003, 24:278-285.
77. Lee A.W., Wang N., Hornell T.M., Harding J.J., Deshpande C., Hertel L., Lacaille V., Pashine A., Macaubas C., Mocarski E.S., Mellins E.D. Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels. Molecular Immunology 2011;48: 1160-1167.